Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalSTU:GYX Gross Margin % is 143.22% as of Dec. 2025, which is 106% above its 10-year median of 69.57. The stock has 5 warning signs investors should review. Among 732 Biotechnology companies, Futura Medical ranks better than 63.11% on this metric.
The historical rank and industry rank for Futura Medical's Gross Margin % or its related term are showing as below:
STU:GYX'
s Gross Margin % Range Over the Past 10 Years
Min: 57.21 Med: 69.57 Max: 73.07
Current: 73.07
During the past 13 years, the highestGross Margin % of Futura Medical was 73.07%. The lowest was 57.21%. And the median was 69.57%.
STU:GYX's Gross Margin % is ranked better than 63.11% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs STU:GYX: 73.07
Futura Medical had a gross margin of 143.22% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Futura Medical was 0.00% per year.
Futura Medical (STU:GYX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Futura Medical had a gross margin of 143.22% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Futura Medical Gross Margin % Related Terms
Futura Medical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Futura Medical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:GYX vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Futura Medical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Futura Medical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Futura Medical (STU:GYX) has a Gross Margin % of 143.22% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Futura Medical and its competitors. This is 106% above median its historical median of 69.57. Over the past decade, Futura Medical's Gross Margin % has ranged from 57.21 to 73.07. According to the industry distribution chart, Futura Medical ranks #270 out of 732 companies in the Biotechnology industry, placing it in the top 36.9%.
Is Futura Medical's Gross Margin % too high?
Futura Medical's current Gross Margin % of 143.22% is 106% above median its 10-year median of 69.57. Over the past 10 years, this metric has ranged from a low of 57.21 to a high of 73.07. The Biotechnology industry median Gross Margin % is 60.91. Futura Medical's value of 143.22% is 135.2% above this industry median. Based on the distribution chart, Futura Medical ranks #270 out of 732 companies in the Biotechnology industry, which is above the industry midpoint.
How does Futura Medical's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #270 out of 732 companies for Gross Margin %. This puts Futura Medical in the upper half of its industry. The industry median Gross Margin % is 60.91. Futura Medical's value of 143.22% is 135.2% above this benchmark. Historically, Futura Medical's own Gross Margin % has ranged from 57.21 to 73.07 over the past decade. While the company's 10-year median is 69.57 vs. the industry median of 60.91, Futura Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Futura Medical's current Gross Margin % of 143.22% is 135.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Futura Medical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Futura Medical's current Gross Margin % is 143.22%, which is 106% above median its own 10-year median of 69.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Futura Medical (STU:GYX) has a current Gross Margin % of 143.22%. The current Gross Margin % is 143.22%, which is 106% above median its 10-year median of 69.57 and 135.2% above the Biotechnology industry median of 60.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Futura Medical (STU:GYX), the current Gross Margin % is 143.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:GYX has been successfully added to your 
